FDA Grants Breakthrough Therapy Designation to JNJ-6372 in mNSCLC
This Breakthrough Therapy designation is supported by results from a phase I, first-in-human study of JNJ- 61186372, ...as monotherapy and in combination with novel third generation EGFR tyrosine kinase inhibitor (TKI) lazeritinib...
Yuhan signs $1.25 billion licensing deal with Janssen
Lasertinib(GNS-1480), discovered by Genosco, was out-licensed to Janssen.
Early results from a 3rd gen EGFR-TKI in advanced NSCLC
Dr. Cho speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase I/II trial of lazertinib(GNS-1480, YH25448), a highly selective and irreversible investigational 3rd-generation EGFR-TKI.
YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results
Genosco's pipeline GNS-1480 (YH25448) was presented at ASCO 2018. *ASCO stands for American Society of Clinical Oncology Annual Meeting.
YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results
ASCO 2018 Poster Board: #356 • Abstract 9033; Byoung Chul Cho - First Author, Severence Hospital
Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448(GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018
Business Wire * May 16, 2018; Abstract - https://meetinglibrary.asco.org/record/161036/abstract